BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saxena A. Drug targets for COVID-19 therapeutics: Ongoing global efforts. J Biosci 2020;45:87. [PMID: 32661214 [PMID: 32661214 DOI: 10.1007/s12038-020-00067-w] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Nag A, Dasgupta A, Sengupta S, Lai TK, Acharya K. An in-silico pharmacophore-based molecular docking study to evaluate the inhibitory potentials of novel fungal triterpenoid Astrakurkurone analogues against a hypothetical mutated main protease of SARS-CoV-2 virus. Comput Biol Med 2023;152:106433. [PMID: 36565483 DOI: 10.1016/j.compbiomed.2022.106433] [Reference Citation Analysis]
2 Chavda VP, Prajapati R, Lathigara D, Nagar B, Kukadiya J, Redwan EM, Uversky VN, Kher MN, Rajvi P. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther 2022. [PMID: 35604379 DOI: 10.1080/14712598.2022.2078160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
3 Mujwar S, Sun L, Fidan O. In silico evaluation of food-derived carotenoids against SARS-CoV-2 drug targets: Crocin is a promising dietary supplement candidate for COVID-19. J Food Biochem 2022;:e14219. [PMID: 35545850 DOI: 10.1111/jfbc.14219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Gallo G, Barcick U, Coelho C, Salardani M, Camacho MF, Cajado-carvalho D, Loures FV, Serrano SM, Hardy L, Zelanis A, Würtele M. A Proteomics-MM/PBSA Dual Approach for the Analysis of SARS-CoV-2 Main Protease Substrate Peptide Specificity. Peptides 2022. [DOI: 10.1016/j.peptides.2022.170814] [Reference Citation Analysis]
5 Mahanta S, Naiya T, Biswas K, Changkakoti L, Mohanta YK, Tanti B, Mishra AK, Mohanta TK, Sharma N. Plant Source Derived Compound Exhibited In Silico Inhibition of Membrane Glycoprotein In SARS-CoV-2: Paving the Way to Discover a New Class of Compound For Treatment of COVID-19. Front Pharmacol 2022;13:805344. [DOI: 10.3389/fphar.2022.805344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tian X, Shen L, Gao P, Huang L, Liu G, Zhou L, Peng L. Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion. Front Microbiol 2022;13:740382. [DOI: 10.3389/fmicb.2022.740382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Sharma M, Uttam Singh T, Cholenahalli Lingaraju M, Parida S. Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19. Biotechnology to Combat COVID-19 2022. [DOI: 10.5772/intechopen.96899] [Reference Citation Analysis]
8 Chavda VP, Kapadia C, Soni S, Prajapati R, Chauhan SC, Yallapu MM, Apostolopoulos V. A global picture: therapeutic perspectives for COVID-19. Immunotherapy. [DOI: 10.2217/imt-2021-0168] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 21.0] [Reference Citation Analysis]
9 Sasidharan S, Sarkar N, Saudagar P. Discovery of compounds inhibiting SARS-COV-2 multi-targets. J Biomol Struct Dyn 2022;:1-16. [PMID: 34994297 DOI: 10.1080/07391102.2021.2025149] [Reference Citation Analysis]
10 Dubey R, Dubey K. SARS-CoV-2: Potential Drug Targets and Its Virtual Screening. Modeling, Control and Drug Development for COVID-19 Outbreak Prevention 2022. [DOI: 10.1007/978-3-030-72834-2_8] [Reference Citation Analysis]
11 Mehyar N, Mashhour A, Islam I, Alhadrami HA, Tolah AM, Alghanem B, Alkhaldi S, Somaie BA, Al Ghobain M, Alobaida Y, Alaskar AS, Boudjelal M. Discovery of Zafirlukast as a novel SARS-CoV-2 helicase inhibitor using in silico modelling and a FRET-based assay. SAR QSAR Environ Res 2021;32:963-83. [PMID: 34818959 DOI: 10.1080/1062936X.2021.1993995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Banerjee S, Yadav S, Banerjee S, Fakayode SO, Parvathareddy J, Reichard W, Surendranathan S, Mahmud F, Whatcott R, Thammathong J, Meibohm B, Miller DD, Jonsson CB, Dubey KD. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study. J Chem Inf Model 2021;61:5469-83. [PMID: 34666487 DOI: 10.1021/acs.jcim.1c00524] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
13 Agrawal PK, Agrawal C, Blunden G. Pharmacological Significance of Hesperidin and Hesperetin, Two Citrus Flavonoids, as Promising Antiviral Compounds for Prophylaxis Against and Combating COVID-19. Natural Product Communications 2021;16:1934578X2110425. [DOI: 10.1177/1934578x211042540] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Tiwari V, Kumar M, Tiwari A, Sahoo BM, Singh S, Kumar S, Saharan R. Current trends in diagnosis and treatment strategies of COVID-19 infection. Environ Sci Pollut Res Int 2021;28:64987-5013. [PMID: 34601675 DOI: 10.1007/s11356-021-16715-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Oâ Donnell HR, Tummino TA, Bardine C, Craik CS, Shoichet BK. Colloidal aggregators in biochemical SARS-CoV-2 repurposing screens. bioRxiv 2021:2021. [PMID: 34494023 DOI: 10.1101/2021.08.31.458413] [Reference Citation Analysis]
16 Arora G, Joshi J, Mandal RS, Shrivastava N, Virmani R, Sethi T. Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19. Pathogens 2021;10:1048. [PMID: 34451513 DOI: 10.3390/pathogens10081048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Saric B, Tomic N, Kalajdzic A, Pojskic N, Pojskic L. In silico analysis of selected components of grapefruit seed extract against SARS-CoV-2 main protease. The EuroBiotech Journal 2021;5:5-12. [DOI: 10.2478/ebtj-2021-0015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Naik B, Mattaparthi VSK, Gupta N, Ojha R, Das P, Singh S, Prajapati VK, Prusty D. Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications. J Biomol Struct Dyn 2022;40:9543-67. [PMID: 34062110 DOI: 10.1080/07391102.2021.1931451] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Rasool N, Yasmin F, Sahai S, Hussain W, Inam H, Arshad A. Biological perspective of thiazolide derivatives against Mpro and MTase of SARS-CoV-2: Molecular docking, DFT and MD simulation investigations. Chem Phys Lett 2021;771:138463. [PMID: 33716307 DOI: 10.1016/j.cplett.2021.138463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
20 Amaral JL, Oliveira JTA, Lopes FES, Freitas CDT, Freire VN, Abreu LV, Souza PFN. Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease. J Biomol Struct Dyn 2022;40:8925-37. [PMID: 33949286 DOI: 10.1080/07391102.2021.1920464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Goyal M, Tewatia N, Vashisht H, Jain R, Kumar S. Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review. J Infect Public Health 2021;14:910-21. [PMID: 34119845 DOI: 10.1016/j.jiph.2021.04.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
22 Shaji D, Yamamoto S, Saito R, Suzuki R, Nakamura S, Kurita N. Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations. Biophys Chem 2021;275:106608. [PMID: 33962341 DOI: 10.1016/j.bpc.2021.106608] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
23 Arif A, Ansari S, Ahsan H, Mahmood R, Khan FH. An overview of Covid-19 pandemic: immunology and pharmacology. J Immunoassay Immunochem 2021;:1-20. [PMID: 33788668 DOI: 10.1080/15321819.2021.1904414] [Reference Citation Analysis]
24 Amendola G, Ettari R, Previti S, Di Chio C, Messere A, Di Maro S, Hammerschmidt SJ, Zimmer C, Zimmermann RA, Schirmeister T, Zappalà M, Cosconati S. Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening. J Chem Inf Model 2021;61:2062-73. [PMID: 33784094 DOI: 10.1021/acs.jcim.1c00184] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
25 Chenchula S, Ray A, Sadasivam B. Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review. Drug Res (Stuttg) 2021;71:295-301. [DOI: 10.1055/a-1397-6763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Tuli HS, Sood S, Kaur J, Kumar P, Seth P, Punia S, Yadav P, Sharma AK, Aggarwal D, Sak K. Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. 3 Biotech 2021;11:110. [PMID: 33552835 DOI: 10.1007/s13205-021-02644-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Said MA, Albohy A, Abdelrahman MA, Ibrahim HS. Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: Lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics. Eur J Pharm Sci 2021;160:105744. [PMID: 33540040 DOI: 10.1016/j.ejps.2021.105744] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
28 Chakraborty C, Bhattacharya M, Mallick B, Sharma AR, Lee SS, Agoramoorthy G. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development. Expert Rev Clin Pharmacol 2021;14:225-38. [PMID: 33423554 DOI: 10.1080/17512433.2021.1874348] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
29 Shagufta, Ahmad I. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. Eur J Med Chem 2021;213:113157. [PMID: 33486200 DOI: 10.1016/j.ejmech.2021.113157] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
30 Mashe T, Takawira FT, Martins LDO, Gudza-mugabe M, Chirenda J, Munyanyi M, Chaibva BV, Tarupiwa A, Gumbo H, Juru A, Nyagupe C, Phiri I, Manangazira P, Goredema A, Danda S, Chabata I, Jonga J, Munharira R, Masunda K, Mukeredzi I, Mangwanya D, Trotter A, Viet TL, Kay G, Baker D, Thilliez G, Gutierrez A, O’grady J, Hove M, Mutapuri-zinyowera S, Page AJ, Kingsley RA, Mhlanga G, The COVID-19 Genomics UK (COG-UK) Consortium, SARS-CoV-2 Research Group. Genomic epidemiology of the SARS-CoV-2 epidemic in Zimbabwe: Role of international travel and regional migration in spread.. [DOI: 10.1101/2021.01.04.20232520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Nimgampalle M, Devanathan V, Saxena A. Importance of in silico studies on the design of novel drugs from medicinal plants against 21st-century pandemics: past, present, and future. Pandemic Outbreaks in the 21st Century 2021. [DOI: 10.1016/b978-0-323-85662-1.00013-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Rathod K, Dhingra N, Dakshinamurthy S, Viswanath B. Could repurposing existing vaccines and antibiotics help to control the COVID-19 pandemic? Pandemic Outbreaks in the 21st Century 2021. [DOI: 10.1016/b978-0-323-85662-1.00020-3] [Reference Citation Analysis]
33 Joshi R, Bansal S, Malik D, Singla R, Mishra A, Prakash A, Medhi B. Computational Modeling of ACE2 Inhibitors for Development of Drugs Against Coronaviruses. Methods in Pharmacology and Toxicology 2021. [DOI: 10.1007/7653_2020_71] [Reference Citation Analysis]
34 Das G, Das T, Chowdhury N, Chatterjee D, Bagchi A, Ghosh Z. Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19. Genomics 2021;113:1129-40. [PMID: 33189776 DOI: 10.1016/j.ygeno.2020.11.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
35 Li Weng Y, Naik SR, Dingelstad N, Kalyaanamoorthy S, Ganesan A. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 Main Protease complexes reveal the role of a lateral pocket in enhancing the ligand affinity.. [DOI: 10.1101/2020.10.31.363309] [Reference Citation Analysis]
36 Chen JM. Live unattenuated vaccines for controlling viral diseases, including COVID-19. J Med Virol 2021;93:1943-9. [PMID: 32833258 DOI: 10.1002/jmv.26453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Karateev DE, Luchikhina EL. Immunomodulatory drug therapy for the disease caused by SARS-CoV-2 infection (COVID-19). Alʹm klin med 2020;48:51-67. [DOI: 10.18786/2072-0505-2020-48-036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]